Infant formula powder player Bubs Australia (ASX:BUB) has predicted it will have the US FDA’s full blessings in just over a year’s time. You may remember the stock causing a lot of hubbub during the COVID years when a baby formula shortage in the United States caused eyes to start scouring the local market for value. Bubs and A2 Milk were widely the most popular stocks attached to that proposition. Now, the company has seen its 400th patient enrolled in an ongoing infant powder trial to establish safety and benefits of the product. That study comes on the back of a 2022 regulatory directive fr…